Targeting RAS for Pancreatic Cancer Interception
Summary: Multiple strategies to target RAS are now available to treat pancreatic cancer. As pancreatic precancers also have KRAS mutations, these tools hold great promise for cancer interception.
Authors
- Sandra Misale (ORCID: https://orcid.org/0000-0002-6031-0137)
- Neeha Zaidi (ORCID: https://orcid.org/0000-0002-0094-0049)
- Alison Patricia Klein (ORCID: https://orcid.org/0000-0003-2737-8399)
- Laura DeLong Wood (ORCID: https://orcid.org/0000-0003-3096-652X)
- Elizabeth M. Jaffee (ORCID: https://orcid.org/0000-0003-3841-6549)
Institutions
- Johns Hopkins University (US)
- Johns Hopkins Medicine (US)
- Sidney Kimmel Comprehensive Cancer Center (US)
- University of Baltimore (US)
Publication Details
- Journal
- Cancer Discovery
- Published
- 2026-09-22
- DOI
- https://doi.org/10.1158/2159-8290.cd-26-1179
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00